SCHEMBL22493213

SCHEMBL22493213

CON(C)C(=O)Cc1ccc2[nH]c(=O)n(C)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.46
▸ LMNA P02545 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ PGR P06401 2/20 0.40
▸ BRD4 O60885 1/20 0.38
▸ HTR1A P08908 1/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HPGD P15428 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ PDE2A O00408 2/20 0.35
▸ PDE3B Q13370 2/20 0.35
▸ PDE3A Q14432 2/20 0.35
▸ P2RY12 Q9H244 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22493184 0.82 TSHR (0.54) MAOBLMNAPGRBRD4HTR1A
SCHEMBL22493206 0.80 MAOB (0.50) MAOBLMNAPGRBRD4HTR1A
SCHEMBL21156816 0.78 LMNA (0.43) MAOBLMNAPGRBRD4HPGD
SCHEMBL30279787 0.75 MAOB (0.53) MAOBLMNAPGRBRD4HTR1A
SCHEMBL20529102 0.75 MAOB (0.53) MAOBLMNAPGRBRD4HTR1A
SCHEMBL12727792 0.73 MAOB (0.55) MAOBLMNAPGRBRD4HTR1A
SCHEMBL3923772 0.72 MAOB (0.53) MAOBLMNAPGRBRD4HTR1A
SCHEMBL14582468 0.72 MAOB (0.53) MAOBLMNAPGRBRD4HTR1A
SCHEMBL3921263 0.72 MAOB (0.48) MAOBLMNAPGRBRD4HPGD
SCHEMBL12881773 0.71 MAOB (0.52) MAOBLMNAPGRBRD4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11547712-B2 Kinase inhibitor compounds and compositions and methods of use ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-01-10 — — US disclosed
US-20200306257-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2020-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200306257-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE MAP3K20, MAP3K1, PACSIN2 MAOB 1868/4885LMNA 1766/4885PARP1 2249/4885
US-11547712-B2 Kinase inhibitor compounds and compositions and methods of use MAP3K20, MAP3K1, PACSIN2 MAOB 1868/4885LMNA 1766/4885PARP1 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback